92 related articles for article (PubMed ID: 31253869)
1. Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
Saigi M; Alburquerque-Bejar JJ; Sanchez-Cespedes M
Oncogene; 2019 Aug; 38(31):5921-5932. PubMed ID: 31253869
[TBL] [Abstract][Full Text] [Related]
2. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
McGranahan N; Rosenthal R; Hiley CT; Rowan AJ; Watkins TBK; Wilson GA; Birkbak NJ; Veeriah S; Van Loo P; Herrero J; Swanton C;
Cell; 2017 Nov; 171(6):1259-1271.e11. PubMed ID: 29107330
[TBL] [Abstract][Full Text] [Related]
3. Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the
Shen T; Chen Z; Zhao ZJ; Wu J
Oncotarget; 2017 Sep; 8(37):60975-60986. PubMed ID: 28977839
[TBL] [Abstract][Full Text] [Related]
4. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.
Skoulidis F; Heymach JV
Nat Rev Cancer; 2019 Sep; 19(9):495-509. PubMed ID: 31406302
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
Bodor JN; Boumber Y; Borghaei H
Cancer; 2020 Jan; 126(2):260-270. PubMed ID: 31691957
[TBL] [Abstract][Full Text] [Related]
6. Genomic and immune profiling of pre-invasive lung adenocarcinoma.
Chen H; Carrot-Zhang J; Zhao Y; Hu H; Freeman SS; Yu S; Ha G; Taylor AM; Berger AC; Westlake L; Zheng Y; Zhang J; Ramachandran A; Zheng Q; Pan Y; Zheng D; Zheng S; Cheng C; Kuang M; Zhou X; Zhang Y; Li H; Ye T; Ma Y; Gao Z; Tao X; Han H; Shang J; Yu Y; Bao D; Huang Y; Li X; Zhang Y; Xiang J; Sun Y; Li Y; Cherniack AD; Campbell JD; Shi L; Meyerson M
Nat Commun; 2019 Nov; 10(1):5472. PubMed ID: 31784532
[TBL] [Abstract][Full Text] [Related]
7. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer.
Gong K; Guo G; Panchani N; Bender ME; Gerber DE; Minna JD; Fattah F; Gao B; Peyton M; Kernstine K; Mukherjee B; Burma S; Chiang CM; Zhang S; Amod Sathe A; Xing C; Dao KH; Zhao D; Akbay EA; Habib AA
Nat Cancer; 2020 Apr; 1(4):394-409. PubMed ID: 33269343
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity.
Mahadevan NR; Knelson EH; Wolff JO; Vajdi A; Saigí M; Campisi M; Hong D; Thai TC; Piel B; Han S; Reinhold BB; Duke-Cohan JS; Poitras MJ; Taus LJ; Lizotte PH; Portell A; Quadros V; Santucci AD; Murayama T; Cañadas I; Kitajima S; Akitsu A; Fridrikh M; Watanabe H; Reardon B; Gokhale PC; Paweletz CP; Awad MM; Van Allen EM; Lako A; Wang XT; Chen B; Hong F; Sholl LM; Tolstorukov MY; Pfaff K; Jänne PA; Gjini E; Edwards R; Rodig S; Reinherz EL; Oser MG; Barbie DA
Cancer Discov; 2021 Aug; 11(8):1952-1969. PubMed ID: 33707236
[TBL] [Abstract][Full Text] [Related]
9. Immune Escape Mechanisms in Non Small Cell Lung Cancer.
Anichini A; Perotti VE; Sgambelluri F; Mortarini R
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33276569
[TBL] [Abstract][Full Text] [Related]
10. Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.
Castro A; Ozturk K; Pyke RM; Xian S; Zanetti M; Carter H
BMC Med Genomics; 2019 Jul; 12(Suppl 6):107. PubMed ID: 31345234
[TBL] [Abstract][Full Text] [Related]
11. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.
Lawson KA; Sousa CM; Zhang X; Kim E; Akthar R; Caumanns JJ; Yao Y; Mikolajewicz N; Ross C; Brown KR; Zid AA; Fan ZP; Hui S; Krall JA; Simons DM; Slater CJ; De Jesus V; Tang L; Singh R; Goldford JE; Martin S; Huang Q; Francis EA; Habsid A; Climie R; Tieu D; Wei J; Li R; Tong AHY; Aregger M; Chan KS; Han H; Wang X; Mero P; Brumell JH; Finelli A; Ailles L; Bader G; Smolen GA; Kingsbury GA; Hart T; Kung C; Moffat J
Nature; 2020 Oct; 586(7827):120-126. PubMed ID: 32968282
[TBL] [Abstract][Full Text] [Related]
12. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses.
Zhang XS; Zhou HC; Wei P; Chen L; Ma WH; Ding L; Liang SC; Chen BD
World J Gastrointest Oncol; 2023 Dec; 15(12):2138-2149. PubMed ID: 38173440
[TBL] [Abstract][Full Text] [Related]
13. The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study.
Samejima H; Kojima K; Fujiwara A; Tokunaga T; Okishio K; Yoon H
BMC Cancer; 2023 Nov; 23(1):1107. PubMed ID: 37964220
[TBL] [Abstract][Full Text] [Related]
14. Microscopical Variables and Tumor Inflammatory Microenvironment Do Not Modify Survival or Recurrence in Stage I-IIA Lung Adenocarcinomas.
Dell'Amore A; Bonis A; Melan L; Silvestrin S; Cannone G; Shamshoum F; Zampieri A; Pezzuto F; Calabrese F; Nicotra S; Schiavon M; Faccioli E; Mammana M; Comacchio GM; Pasello G; Rea F
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760512
[TBL] [Abstract][Full Text] [Related]
15. MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.
Alburquerque-Bejar JJ; Navajas-Chocarro P; Saigi M; Ferrero-Andres A; Morillas JM; Vilarrubi A; Gomez A; Mate JL; Munoz-Marmol AM; Romero OA; Blecua P; Davalos V; Esteller M; Pros E; Llabata P; Torres-Diz M; Esteve-Codina A; Sanchez-Cespedes M
Cell Rep Med; 2023 Apr; 4(4):101006. PubMed ID: 37044092
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer.
Huang H; Chen Y; Weng X; Li S; Zhang L; Chen P
Cancer Cell Int; 2022 Aug; 22(1):261. PubMed ID: 35989349
[TBL] [Abstract][Full Text] [Related]
17. Integrated screens uncover a cell surface tumor suppressor gene
Wang C; Feng X; Su D; Chen Z; Wang S; Tang M; Huang M; Nie L; Zhang H; Li S; Yin L; Johnson RL; Hart T; Chen J
Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2121779119. PubMed ID: 35704761
[TBL] [Abstract][Full Text] [Related]
18. Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of
Cucurull M; Notario L; Sanchez-Cespedes M; Hierro C; Estival A; Carcereny E; Saigí M
Front Oncol; 2021; 11():793121. PubMed ID: 35096591
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathology of Lung Cancer.
J Saller J; Boyle TA
Cold Spring Harb Perspect Med; 2022 Mar; 12(3):. PubMed ID: 34751163
[TBL] [Abstract][Full Text] [Related]
20. Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications.
Desaulniers D; Vasseur P; Jacobs A; Aguila MC; Ertych N; Jacobs MN
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
